Chemotherapy

Chemotherapy has been studied in 359 papers since 2001: 10 trials and 226 observational studies in people, 19 in animals, 1 in cells, 92 reviews; 105 in the past year. The newest story, Nov 12, 2026: “Later Hodgkin lymphoma treatment linked to lower solid cancer risk”.

Intervention

359 papers study it180 findingsUpdated

Research on it is growing 6% faster than aging research as a whole: 164 papers in the latest year counted

12 new papers in 30 daysSee all 357 papers on chemotherapy

At a glance

Human studies link chemotherapy with greater frailty and higher biological age in cancer patients; independent labs report the frailty increase, while a breast cancer cohort shows later frailty improvement. Mouse studies report cellular senescence. Some authors have company affiliations and some papers declare company ties; a trial is company-sponsored, but no registered trials are classified as aging-related.

180 findings in 133 papers from 2015 to 2026, 20 of them since April 2026

Independent labs found the same change in mice and people. 87 independent labs in 23 countries; 300 trials, none about aging, 57 with no results posted.

“Chemotherapy was associated with increased risk of CVD.”
Cardiovascular disease and stroke following cancer and cancer treatment in older adultsCancer2024doi:10.1002/cncr.35503

13 of its findings point the other way.

Mice and humans: replicated by independent labs. Cells: a single group. Worms or flies: nothing yet.
  • 87 independent labs in 23 countries
  • 13 findings against
  • 300 trials, none about aging, 57 with no results posted
  • Funders: National Cancer Institute and others
  • 16 of 152 findings with company ties
  • 1 of 300 trials sponsored by its developers
  • Human trial10
  • Humans225
  • Animals19
  • Cells1
  • In silico5

Studies in people

2 studies gave chemotherapy to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on cognitive function0.6 (95% CI -0.3 to 1.6) at 1 year, 0.9 (95% CI -1.0 to 2.8) at 3 years (P = 0.136)

no change: Has no effect on mild cognitive impairment28.6% vs 41.7% (P = 0.548)

Randomized trial1-yearWomen70 to 80 yearsOlder adults; HER2-positive breast cancerBreast cancer research and treatment, Jun 2, 2021

up: Increases mTOR phosphorylation at Ser2448

Trial4-7 weeks before exercise, then 10 weeks continued10 peopleDuring chemotherapy in cancer patientsJournal of cancer research and clinical oncology, Apr 9, 2019

What did studies of chemotherapy find?

80

Studies of chemotherapy measured 80 outcomes; the most studied are cellular senescence (12 studies), physical function (9) and cognitive function (6).

Cellular senescence

upin humans5upin reviews3upin mice2upin animals1+1

12 studies
  1. Chemotherapy is linked with higher cellular senescence in humans (colorectal cancer liver metastases) (5-fold relative to aging).

    Humanscolorectal cancer liver metastaseslivern = 24

  2. Chemotherapy is linked with cellular senescence in myofibroblastic cancer-associated fibroblasts within the tumor core.

    Humansin myofibroblastic cancer-associated fibroblasts within the tumor core

    Senescent support cells cluster at human pancreatic tumor edges

    Cellular and molecular gastroenterology and hepatology
  3. Chemotherapy induces cellular senescence in humans (systemic chemotherapy).

    Reviewsystemic chemotherapy

  4. Chemotherapy induces cellular senescence in humans (cancer therapeutics).

    Reviewcancer therapeutics

  5. Chemotherapy induces cellular senescence.

    Review

  6. Chemotherapy induces cellular senescence (restricted to CAR cells and bone marrow adipocytes).

    Animalsrestricted to CAR cells and bone marrow adipocytesbone marrow

  7. Chemotherapy increases cellular senescence in pancreatic-tumor-bearing mice.

    Animalsin pancreatic-tumor-bearing miceskeletal muscle

  8. Chemotherapy induces cellular senescence.

    Review

  9. Chemotherapy induces cellular senescence in mice (HSCT chemotherapy).

    AnimalsHSCT chemotherapybrain

  10. Chemotherapy induces cellular senescence in humans.

    Review

All 12

More on Cellular senescence

Physical function

downin humans5no changein humans3upin humans1

9 studies
  1. Chemotherapy improves physical function in humans (acute myeloid leukemia) (51.6% improved, 22.6% stable).

    Human trialacute myeloid leukemiathree monthsn = 43

  2. Chemotherapy is linked with worse physical function in humans (-7.1 at year 1).

    Humansyear 1females

  3. Chemotherapy is linked with worse physical function in humans (early-stage breast cancer) (median change -5 (IQR -20, 0) vs 0 (IQR -5, 5), p < 0.001).

    Humansearly-stage breast cancerfemalesn = 444

  4. Chemotherapy is linked with worse physical function in local endometrial cancer, in the year following diagnosis (-7.9 [95% CI, -12.2 to -3.6] points per year).

    Humansin local endometrial cancer, in the year following diagnosisfemales

  5. Chemotherapy was not clearly linked with physical function in humans (metastatic castration-resistant prostate cancer).

    Humansmetastatic castration-resistant prostate cancer6 monthsmalesn = 198

  6. Chemotherapy was not clearly linked with physical function in humans (Estrogen receptor positive breast cancer survivors on adjuvant aromatase inhibitors) (Short physical performance battery: controls 10.1±1.8 versus cases 10.4±1.1; p=0.52).

    HumansEstrogen receptor positive breast cancer survivors on adjuvant aromatase inhibitorsadjuvant1–2 years after definitive surgeryfemalesn = 56

  7. Chemotherapy was not clearly linked with physical function in humans (metastatic castration-resistant prostate cancer).

    Humansmetastatic castration-resistant prostate cancermales

  8. Chemotherapy impairs physical function in postmenopausal breast cancer survivors.

    Reviewin postmenopausal breast cancer survivorsfemales

  9. Chemotherapy impairs physical function in cancer survivors (82% of 23 studies).

    Reviewin cancer survivors

Cognitive function

downin humans3upin humans1no changein humans1downin reviews1

6 studies
  1. Chemotherapy improves cognitive function in humans (acute myeloid leukemia) (38.7% improved, 38.7% stable).

    Human trialacute myeloid leukemiathree monthsn = 43

  2. Chemotherapy showed no clear effect on cognitive function in humans (HER2-positive breast cancer) (0.6 (95% CI -0.3 to 1.6) at 1 year, 0.9 (95% CI -1.0 to 2.8) at 3 years (P = 0.136)).

    Human trialHER2-positive breast cancer1-yearfemales

  3. Chemotherapy is linked with worse cognitive function in humans (long-term breast cancer survivors) (d = -3.9726 [-0.9656, -6.9796], p = 0.01).

    Humanslong-term breast cancer survivors2 yearsfemales

  4. Chemotherapy impairs cognitive function.

    Review

  5. Chemotherapy impairs cognitive function in cancer survivors (74% of 39 studies).

    Reviewin cancer survivors

  6. Chemotherapy impairs cognitive function in patients with cancer.

    Reviewin patients with cancer

Frailty

upin humans3downin humans1

3 studies
  1. Chemotherapy is linked with lower frailty in humans (stage I-III breast cancer, from 4 months to 10 months postchemotherapy initiation) (from 0.055 to 0.049).

    Humansstage I-III breast cancer, from 4 months to 10 months postchemotherapy initiation6 monthsfemales

  2. Chemotherapy is linked with higher frailty in humans (stage I-III breast cancer undergoing adjuvant chemotherapy) (from 0.037 to 0.055).

    Humansstage I-III breast cancer undergoing adjuvant chemotherapy4 months postchemotherapy initiationfemales

  3. Chemotherapy is linked with higher frailty in patients with breast cancer, from before to after chemotherapy (mean frailty score 1.17 to 2.08).

    Humansin patients with breast cancer, from before to after chemotherapyfemalesn = 144

  4. Chemotherapy increases frailty in cancer survivors (80% of 15 studies).

    Reviewin cancer survivors

Body weight

upin humans3

3 studies
  1. Chemotherapy is linked with higher body weight in humans (postoperative breast cancer patients undergoing chemotherapy) (p = 0.001).

    Humanspostoperative breast cancer patients undergoing chemotherapysix weeks periodfemalesn = 60

  2. Chemotherapy is linked with higher body weight in humans (early breast cancer) (1.2 kg).

    Humansearly breast cancerfemalesn = 38

  3. Chemotherapy is linked with higher body weight in humans during chemotherapy.

    Humansduring chemotherapyfemalesn = 55

Biological age

upin humans2upin reviews1

3 studies
  1. Chemotherapy is linked with higher biological age in breast cancer survivors exposed to chemotherapy (1.97 to 2.71 years older, p = .001-.04).

    Humansin breast cancer survivors exposed to chemotherapyblood24 to 36 months after enrollmentfemales

  2. Chemotherapy increases biological age in breast cancer survivors.

    Reviewin breast cancer survivors

  3. Chemotherapy increases biological age.

    Review

Survival

no changein humans1upin humans1

2 studies
  1. Chemotherapy was not clearly linked with survival in humans (lymphoma; compared with full-dose protocols) (p = 0.81).

    Humanslymphoma; compared with full-dose protocolsreduced-dose

  2. Chemotherapy is linked with better survival in cancer patients who died from AD.

    Humansin cancer patients who died from AD

Inflammation

upin humans1upin reviews1

2 studies
  1. Chemotherapy induces inflammation.

    Reviewbrain

  2. Chemotherapy increases inflammation in breast cancer survivors.

    Reviewin breast cancer survivors

More on Inflammation

Dementia

no changein humans2HR 0.826–0.85

2 studies
  1. Chemotherapy was not clearly linked with dementia in humans (breast cancer patients who underwent surgery) (adjusted HR 0.826 (95% CI: 0.532-1.280), adjusted SHR 0.683 (95% CI: 0.422-1.104)).

    Humansbreast cancer patients who underwent surgeryfemalesn = 46,886

  2. Chemotherapy was not clearly linked with dementia in humans (non-central nervous system lymphoma in complete remission after chemotherapy) (HR 0.85, 95% CI 0.70–1.04).

    Humansnon-central nervous system lymphoma in complete remission after chemotherapy

More on Dementia

p16INK4a

upin humans2

2 studies
  1. Chemotherapy is linked with higher p16INK4a in humans (stage I–III breast cancer) (∼14 years vs 2.1 years).

    Humansstage I–III breast cancerperipheral blood T cellsmean 6 years follow-upfemalesn = 119

  2. Chemotherapy is linked with higher p16INK4a in humans (9.6 vs 8.9 log2 p16 units; representing a 25-year age acceleration in survivors).

    Humanschildhood, adolescent, and young adult cancer survivors vs age-matched cancer-free controlsperipheral blood T-lymphocyte

More on p16INK4a

Quality of life improvement

downin humans1

1 study
  1. Chemotherapy decreases quality of life improvement in humans (+0.69 points; SMD: 0.07).

    Human trial12 weeks

    More adults with cancer met activity guidelines after exercise

    Cancers
  2. Chemotherapy decreases quality of life improvement in humans (cancer patients receiving chemotherapy).

    Human trialcancer patients receiving chemotherapy12 weeks

    More adults with cancer met activity guidelines after exercise

    Cancers

Fat mass

upin humans1

1 study
  1. Chemotherapy increases fat mass in the control group (≥10 000 steps/day) (B=2.062 kg, p=0.045).

    Human trialin the control group (≥10 000 steps/day)femalesn = 21

More on Fat mass

HDL-C

downin humans1

1 study
  1. Chemotherapy decreases HDL-C in humans (early breast cancer) (p < 0.001).

    Human trialearly breast cancerfemalesn = 56

More on HDL-C

LDL-C

upin humans1

1 study
  1. Chemotherapy increases LDL-C in humans (early breast cancer) (p = 0.007).

    Human trialearly breast cancerfemalesn = 56

More on LDL-C

Depressive symptoms

downin humans1

1 study
  1. Chemotherapy decreases depressive symptoms in humans (acute myeloid leukemia) (9.4% improved, 53.1% stable).

    Human trialacute myeloid leukemiathree monthsn = 43

All 80

What is chemotherapy linked with?

53

Studies link chemotherapy with 53 measures, most often sarcopenia (3 studies), frailty (2) and bone fracture (2).

Sarcopenia

upin humans3+56%

3 studies
  1. Chemotherapy is associated with sarcopenia in humans (hospitalized cancer patients receiving chemotherapy) (55.7%).

    Humanshospitalized cancer patients receiving chemotherapyn = 131

  2. Chemotherapy is associated with sarcopenia in humans (hospitalized cancer patients undergoing chemotherapy) (55.7%).

    Humanshospitalized cancer patients undergoing chemotherapyn = 131

  3. Chemotherapy is linked with a higher risk of sarcopenia in gastrointestinal cancer patients.

    Humansin gastrointestinal cancer patientsn = 243

More on Sarcopenia

Frailty

mixedin humans1upin humans1

2 studies
  1. Chemotherapy is associated with frailty in humans (Patients with non-Hodgkin lymphoma) (Mean frailty scores: 4.31±2.46 before chemotherapy, 5.22±2.59 at the third cycle, and 4.50±2.65 at the end; peak prevalence 59.3% at the third cycle).

    HumansPatients with non-Hodgkin lymphomaBefore chemotherapy through the end of chemotherapyn = 252

  2. Chemotherapy is associated with frailty in humans (lung cancer treated with chemotherapy).

    Humanslung cancer treated with chemotherapyn = 302

Bone fracture

upin humans2HR 1.31

2 studies
  1. Chemotherapy is linked with a higher risk of bone fracture in humans (lung cancer survivors, overall follow-up) (csHR 1.32, 95% CI 1.21-1.45).

    Humanslung cancer survivors, overall follow-up

  2. Chemotherapy is linked with a higher risk of bone fracture in humans within 5 years of diagnosis (HR 1.31, 95% CI 1.09-1.57).

    Humanswithin 5 years of diagnosis

More on Bone fracture

Cognitive frailty

upin humans2+45%

2 studies
  1. Chemotherapy is associated with cognitive frailty in humans (esophageal cancer undergoing chemotherapy) (45.1%).

    Humansesophageal cancer undergoing chemotherapyn = 246

  2. Chemotherapy is linked with a higher risk of cognitive frailty in humans (colorectal cancer) (p < 0.05).

    Humanscolorectal cancer

Chemotherapy-related cognitive impairment

upin humans2+80%

2 studies
  1. Chemotherapy raises the risk of chemotherapy-related cognitive impairment in humans (cancer patients treated with chemotherapy) (up to 80%).

    Reviewcancer patients treated with chemotherapy

  2. Chemotherapy is associated with chemotherapy-related cognitive impairment in humans (breast cancer survivors) (18.6% to 27% (objective), 7.6% to 49% (subjective)).

    Reviewbreast cancer survivors

More on Chemotherapy-related cognitive impairment

Transition from low frailty to high frailty

upin humans1

1 study
  1. Chemotherapy is associated with transition from low frailty to high frailty in humans (patients with colorectal cancer).

    Humanspatients with colorectal cancer1 to 6 months postoperativelyn = 207

Overall survival

upin humans1

1 study
  1. Chemotherapy is associated with overall survival in humans (high-risk breast cancer identified by FINE Index).

    Humanshigh-risk breast cancer identified by FINE Index

Mortality

downin humans1HR 0.44

1 study
  1. Chemotherapy is linked with a lower risk of mortality in humans (Stage IV elderly gastric adenocarcinoma) (HR=0.44).

    HumansStage IV elderly gastric adenocarcinoma

Functional status

downin humans1

1 study
  1. Chemotherapy is associated with functional status in humans (colorectal cancer).

    Humanscolorectal cancern = 128

Secondary malignancy

upin humans1

1 study
  1. Chemotherapy raises the risk of secondary malignancy in humans (systemic chemotherapy).

    Reviewsystemic chemotherapy

More on Secondary malignancy

Cardiovascular disease

upin humans1

1 study
  1. Chemotherapy raises the risk of cardiovascular disease in humans.

    Human trial

More on Cardiovascular disease

Body weight loss

upin humans1

1 study
  1. Chemotherapy predicts body weight loss in humans (Head and neck cancer during radiotherapy).

    Human trialHead and neck cancer during radiotherapy

All 53

What acts on chemotherapy?

3

Studies name 3 things that act on chemotherapy: Older age, global risk indicator and frailty.

Older age

downin humans1OR 0.4

1 study
  1. older age is linked with lower chemotherapy in humans following resection for localized pancreatic cancer (adjusted OR: 0.4, 95% CI [0.3-0.4], p < 0.001).

    Humansfollowing resection for localized pancreatic cancer

    Broadly similar quality of life by age in localized pancreatic cancer

    European journal of cancer (Oxford, England : 1990)

Global risk indicator

downin humans1OR 0.5

1 study
  1. Global risk indicator is linked with lower chemotherapy in humans (older home care recipients with diffuse large B-cell lymphoma) (OR 0.50 (95% CI 0.39-0.64)).

    Humansolder home care recipients with diffuse large B-cell lymphoman = 1,232

More on Global risk indicator

Frailty

downin humans1

1 study
  1. Frailty is linked with lower chemotherapy in humans after recurrence after hepatectomy for colorectal liver metastasis.

    Humansafter recurrence after hepatectomy for colorectal liver metastasis

Has chemotherapy been tested in people?

0 of 300 about aging

Yes: 10 trials and 226 observational studies in people have been published, and 300 trials are registered.

Latest change Triple-negative breast cancer: Phase 2 → Phase 3Nov 12, 2026

In trials

40 of 171

Stopped

  • NCT04031885TerminatedMetastatic breast cancer

    Business decision based on the inability to enroll subjects into the trial

  • NCT00380874TerminatedPain

    See detailed description for termination reason

  • NCT03642132TerminatedOvarian neoplasm

    Phase 3 B9991010 study was stopped due to futility of efficacy at interim analysis on 21Dec2018, and approvals of PARP inhibitors in front-line maintenance setting, Pfizer decided stopping enrollment in the B9991030 study on 19Mar2019.

  • NCT02178397TerminatedLung neoplasm

    lack of recruitment

  • NCT02298166TerminatedLeukemia myeloid acute

    The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an Investigator Initiated Trial this became valid on 2020/03/09

  • NCT00133224TerminatedNeoplasm metastasis

    Accrual and treatment with CG1940/CG8711 stopped due to IDMC recommendation.

All 11

Who is developing chemotherapy?

3 companies: Daiichi Sankyo, Cordgenics and AstraZeneca.

Companies
  • Daiichi SankyoPhase 3gastric cancer, gastroesophageal junction cancer
  • CordgenicsPhase 3recurrent glioblastoma
  • AstraZenecaPhase 3small cell lung carcinoma extensive disease

Trial sponsors

Funding

36 grants since 2016

National Cancer Institute$15.9MNational Institute on Aging$6.4MJapan Society for the Promotion of Science¥35.8M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Chemotherapy is linked to impaired cognition in human studies and induces senescence in mice, both reported by independent labs. Human cognitive results also include null effects and improvement; cancer studies report survival benefits. Some papers declare company ties; none of 206 registered trials is judged aging-related, and 43 ended over a year ago without posted results or a citing paper.

  2. Summary rewritten as its findings changed.

    As it read before

    A human trial reports increased p16INK4a and Hannum's clock with chemotherapy in women with breast cancer. Human studies also report more nonsynonymous variants in children's normal tissues and impaired physical function in women; another trial reports less quality-of-life improvement in cancer patients.

  3. Summary written from the findings.

Latest

Dec 2025: 9Jan 2026: 12Feb 2026: 11Mar 2026: 11Apr 2026: 5May 2026: 6Jun 2026: 6Jul 2026: 7Aug 2026: 6Sep 2026: 8Oct 2026: 10Nov 2026: 798 papers in 12 months
Journal of Clinical Oncology

Later Hodgkin lymphoma treatment linked to lower solid cancer risk

Among female Hodgkin lymphoma survivors, treatment in 2000–2010 was associated with a 25% lower relative risk of solid cancers than treatment in 1954–1989.Among female Hodgkin lymphoma survivors, treatment in 2000–2010 was associated with a 25% lower relative risk of solid cancers than treatment in 1954–1989.

Cohort · 7,428 peoplePopulations

See all 357 papers on chemotherapy